Synlogic (SYBX) Competitors

Skye Bioscience has a consensus target price of $9.80, indicating a potential upside of 1,251.35%. Given Skye Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Skye Bioscience is more favorable than Synlogic.

Synlogic's return on equity of -26.47% beat Skye Bioscience's return on equity.

Synlogic has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market. Comparatively, Skye Bioscience has a beta of 3.03, suggesting that its share price is 203% more volatile than the broader market.

In the previous week, Skye Bioscience had 3 more articles in the media than Synlogic. MarketBeat recorded 3 mentions for Skye Bioscience and 0 mentions for Synlogic. Skye Bioscience's average media sentiment score of 0.26 beat Synlogic's score of 0.00 indicating that Skye Bioscience is being referred to more favorably in the news media.

63.4% of Synlogic shares are held by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are held by institutional investors. 2.6% of Synlogic shares are held by insiders. Comparatively, 6.2% of Skye Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Synlogic has higher revenue and earnings than Skye Bioscience. Synlogic is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks.

Synlogic's return on equity of -26.47% beat Lantern Pharma's return on equity.

In the previous week, Lantern Pharma had 8 more articles in the media than Synlogic. MarketBeat recorded 8 mentions for Lantern Pharma and 0 mentions for Synlogic. Lantern Pharma's average media sentiment score of 1.11 beat Synlogic's score of 0.00 indicating that Lantern Pharma is being referred to more favorably in the media.

Lantern Pharma has higher earnings, but lower revenue than Synlogic. Synlogic is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks.

Lantern Pharma has a beta of 2.1, meaning that its stock price is 110% more volatile than the broader market. Comparatively, Synlogic has a beta of 0.52, meaning that its stock price is 48% less volatile than the broader market.

28.6% of Lantern Pharma shares are owned by institutional investors. Comparatively, 63.4% of Synlogic shares are owned by institutional investors. 8.5% of Lantern Pharma shares are owned by insiders. Comparatively, 2.6% of Synlogic shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

63.4% of Synlogic shares are held by institutional investors. 2.6% of Synlogic shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Polyrizon's return on equity of 0.00% beat Synlogic's return on equity.

In the previous week, Polyrizon had 4 more articles in the media than Synlogic. MarketBeat recorded 4 mentions for Polyrizon and 0 mentions for Synlogic. Polyrizon's average media sentiment score of 1.03 beat Synlogic's score of 0.00 indicating that Polyrizon is being referred to more favorably in the media.

Polyrizon has a beta of -2.04, suggesting that its stock price is 304% less volatile than the broader market. Comparatively, Synlogic has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market.

Polyrizon has higher earnings, but lower revenue than Synlogic.

In the previous week, Werewolf Therapeutics had 2 more articles in the media than Synlogic. MarketBeat recorded 2 mentions for Werewolf Therapeutics and 0 mentions for Synlogic. Synlogic's average media sentiment score of 0.00 beat Werewolf Therapeutics' score of -1.10 indicating that Synlogic is being referred to more favorably in the news media.

Werewolf Therapeutics presently has a consensus price target of $3.75, indicating a potential upside of 775.35%. Given Werewolf Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Werewolf Therapeutics is more favorable than Synlogic.

Synlogic has lower revenue, but higher earnings than Werewolf Therapeutics. Synlogic is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

Werewolf Therapeutics has a beta of 0.41, indicating that its stock price is 59% less volatile than the broader market. Comparatively, Synlogic has a beta of 0.52, indicating that its stock price is 48% less volatile than the broader market.

64.8% of Werewolf Therapeutics shares are owned by institutional investors. Comparatively, 63.4% of Synlogic shares are owned by institutional investors. 23.6% of Werewolf Therapeutics shares are owned by insiders. Comparatively, 2.6% of Synlogic shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Synlogic's return on equity of -26.47% beat Werewolf Therapeutics' return on equity.